TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02783508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Meperidine
Description: Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered.
Study: NCT03356769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AED
Description: maintain the dosages and the drugs throughout the 3-month observation time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AED
Description: maintain the dosages and the drugs throughout the 3-month observation time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, 5mg/Kg/d, once every day, 25mg per tablets
Study: NCT02805673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathy
Study: NCT00399919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: 2 grams per day for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propionyl-L-Carnitine
Description: 2 grams per day for six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLC
Description: 2 grams/day for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLC
Description: 2 grams/day for six months
Study: NCT02519582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: 2 g per day orally
Study: NCT03872622

Intervention type: OTHER
Group type: OTHER
Intervention: Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire
Description: Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire
Description: Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.
Study: NCT00792675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise training
Description: Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
Study: NCT02958774

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
Study: NCT00559975

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subunit influenza vaccine
Description: 0.5 mL single dose vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted influenza vaccine
Description: 0.5 mL single dose vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine combined with CpG7909
Description: 0.5 ml influenza vaccine combined with 10 mcg of CpG7909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine combine with CpG7909
Description: 0.5 mL single dose vaccine combined with 30 mcg of CpG7909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine combine with CpG7909
Description: 0.5 mL single dose vaccine combined with 100 mcg of CpG7909
Study: NCT03257137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Quality
Description: Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Quality
Description: Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
Study: NCT02367781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
Study: NCT00701558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
Study: NCT01461967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5508887
Description: Single ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5508887
Description: Single doses
Study: NCT00672880

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Study participants continue with their usual medical care, no changes.
Study: NCT01099995

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy
Description: one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
Study: NCT02398500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMG324
Description: IVT injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMG324
Description: IVT injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 mg
Description: IVT injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sham
Description: Fake injection used for masking purposes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Fake injection used for masking purposes
Study: NCT02602288

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ask, Advise, Refer
Description: WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask, Advise, Refer
Description: WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telebased tobacco counseling
Description: Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telebased nutrition counseling
Description: Telephone counseling to promote nutritious eating practices in the family.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone smoking cessation application
Description: Smartphone based application to support smoking cessation efforts

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile phone nutrition application
Description: Smartphone based application to support healthy eating habits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Over the counter nicotine replacement therapy in gum or lozenge form.
Study: NCT02376049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone dipropionate cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glaxal Base cream vehicle
Study: NCT02086591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Study: NCT00612066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Study: NCT01189994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Needling of acupoints, some of them receiving electrostimulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orientation
Description: Orientation sessions focusing in fibromyalgia
Study: NCT04527263

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: measurement of urinary 5-HIAA
Description: urinary assessment of 5-HIAA

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: measurement of urinary 5-HIAA
Description: urinary assessment of 5-HIAA
Study: NCT00789217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate skin test
Description: Intradermal test with immediate reading

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate skin test
Description: Intradermal test with immediate reading

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate skin test
Description: Intradermal test with immediate reading
Study: NCT03830333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline by IV infusion every 8 hours for 4 to 14 days.
Study: NCT02609126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-104IAR
Description: Single, ultrasound-guided injection of EP-104IAR into the knee

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Single, ultrasound-guided injection of vehicle placebo into the knee
Study: NCT01973829

Intervention type: OTHER
Group type: OTHER
Intervention: Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)
Description: This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
Study: NCT02934139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: CFTR modulator that stabilizes CFTR
Study: NCT04454957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastering Diabetes
Description: Virtual (on-line) lifestyle change program, focused on a plant-based, whole food diet and physical activity.
Study: NCT01607866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadrant parotidectomy
Description: Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
Study: NCT02934139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: CFTR modulator that stabilizes CFTR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: CFTR modulator that stabilizes CFTR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: CFTR modulator that stabilizes CFTR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT01010581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC12267 (4SC-101)
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT02147977

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary supplement: n-3 PUFA
Study: NCT04636463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Music
Description: Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
Study: NCT01090856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-dilation side branch
Description: Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
Study: NCT01010581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: oral administration
Study: NCT04255862

Intervention type: DRUG
Group type: OTHER
Intervention: Bimekizumab
Description: Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
Study: NCT00605384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Tenofovir
Description: Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
Study: NCT04255862

Intervention type: DRUG
Group type: OTHER
Intervention: Bimekizumab
Description: Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
Study: NCT00605384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir + continuing Lamivudine
Description: Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
Study: NCT03910491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PriCARE
Description: PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE emphasizes the 3 Ps (Praise, Paraphrase, and Point-out-Behavior). The training initially focuses on parenting skills including giving attention to the child's positive behaviors and ignoring minor misbehaviors. The second phase of training includes teaching techniques for giving children effective commands to set age-appropriate limits. The PriCARE curriculum also includes trauma and stress education components in order to contextualize the use of these skills with the types of behaviors and problems demonstrated by many children who have experienced psychosocial adversity and chronic familial stress. Throughout the curriculum, caregivers are encouraged to practice the skills. PriCARE has been evaluated in the primary care setting and has shown promise. There have been limited studies on PriCARE for foster caregivers.
Study: NCT03969251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (rTMS)
Description: active high frequency repetitive TMS of left Dorsolateral Prefrontal Cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (SS)
Description: repetitive sham rTMS
Study: NCT03180086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast cancer risk report
Description: An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
Study: NCT01290471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1565
Description: U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1565
Description: U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
Study: NCT01607866

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial parotidectomy
Description: Excision of the whole superficial lobe of the parotid gland
Study: NCT01290471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1565
Description: U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
Study: NCT04434222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compressive stockings
Description: Compressive stockings with built in Orthotimer Sensor
Study: NCT00597025

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Food Bar Intelligent Indulgence
Description: Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Food Bar Intelligent Indulgence
Description: Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Food Bar Intelligent Indulgence
Description: Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
Study: NCT02547779

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline
Description: 0.9% Saline will be used whenever an isotonic crystalloid is ordered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiologically-balanced isotonic crystalloid
Description: Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
Study: NCT05531591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Augmentation
Description: Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Augmentation
Description: Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to bupropion
Description: Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Augmentation
Description: Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to nortriptyline
Description: Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml